Abstract

FORMULATION DEVELOPMENT AND EVALUATION OF SUSTAINED RELEASE TABLETS OF LORNOXICAM

Abhishek Pandey* and Sanket Singhal

Abstract

Lornoxicam is a non-steroidal anti-inflammatory drug, Lornoxicam has short half-life (3-5 hr.), makes the development of sustained-release (SR) forms extremely advantageous, lornoxicam is weak acid having pKa 5.1, it has pH dependent solubility, characterized by poor solubility in low pH condition present in stomach, which consequently leads to a delayed onset of its analgesic action. Formulation of sustained release tablet is effective approach for non- steroidal antiinflammatory drug (lornoxicam) for maximum pain relief with prolong drug concentration due to sustained release from tablet matrix. Different formulations (F1- F8) were designed with HPMC (K4M and K100), MCC, PVP k30, magnesium stearate and talc. Pre and post compression parameters for all formulations were studied. Batch F8 selected as optimized batch on the basis of dissolution profile.

Keywords: Lornoxicam, Sustained release, Dissolution, HPMC.